Skye Bioscience, Inc. (SKYE) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.78
↓-19% vs avg
5yr avg: 2.20
30Y Low1.5·High31.8
ROE
↑
-126.8%
↓+72% vs avg
5yr avg: -460.4%
30Y Low-270%·High192%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SKYE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Skye Bioscience, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $32M | $30M | $103M | $19M | $9M | $21M | $9M | $17M | $53M | $5M | $6M |
| Enterprise Value | $26M | $24M | $35M | $22M | $10M | $14M | $8M | $16M | $52M | $5M | $6M |
| P/E Ratio → | -0.64 | — | — | — | — | — | — | 16.54 | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.78 | 1.49 | 1.52 | — | — | 3.61 | 20.53 | 31.79 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SKYE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 7.83 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SKYE Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -126.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -126.8% | -126.8% | -80.5% | — | -1364.2% | -269.9% | -1313.7% | 192.0% | — | — | — |
| ROA | -110.7% | -110.7% | -62.7% | -357.6% | -205.4% | -136.1% | -281.1% | 53.2% | -1526.8% | -702.7% | -165.8% |
| ROIC | -597.3% | -597.3% | -3192.6% | -2123.2% | — | — | — | — | — | — | — |
| ROCE | -131.4% | -131.4% | -90.9% | — | -1247.9% | -200.5% | -432.2% | -646.5% | — | — | -345.2% |
SKYE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $6M exceeds total debt of $273646, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | — | — | 0.36 | 3.32 | 0.71 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.28 | -1.00 | — | — | -1.17 | -2.16 | -2.63 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -26.45 | -40.54 | -28.34 | -10.10 | -8.29 | 2.04 | -201.53 | -4635.68 | — |
Net cash position: cash ($6M) exceeds total debt ($273646)
SKYE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Skye Bioscience, Inc.'s current ratio of 3.30x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.84x to 3.30x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.30 | 3.30 | 16.32 | 0.84 | 0.74 | 2.46 | 3.38 | 2.05 | 0.12 | 0.69 | 0.42 |
| Quick Ratio | 3.30 | 3.30 | 16.32 | 0.84 | 0.74 | 2.46 | 3.38 | 2.05 | 0.12 | 0.69 | 0.42 |
| Cash Ratio | 3.14 | 3.14 | 15.77 | 0.09 | 0.10 | 2.30 | 3.14 | 1.88 | 0.12 | 0.32 | 0.10 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
SKYE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Skye Bioscience, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 6.0% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $40M | $36M | $7M | $2M | $2M | $925683 | $532006 | $525780 | $120766 | $79652 |
Peer Comparison
Compare SKYE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SKYEYou | $32M | -0.6 | — | — | — | — | -126.8% | -597.3% | — |
 ATAI | $964M | -4.3 | — | — | 100.0% | -33341.2% | -82.7% | -45.0% | — |
 CMPS | $902M | -3.0 | — | — | — | — | -565.3% | — | — |
 MNMD | $2B | -10.0 | — | — | — | — | -64.1% | -389.5% | — |
 SNDL | $376M | -33.0 | 7.9 | 8.8 | 27.3% | -0.5% | -1.4% | -0.3% | 3.3 |
 CRBP | $136M | -1.8 | — | — | — | — | -54.2% | -51.4% | — |
 YCBD | $8M | -0.8 | — | — | 56.5% | -11.3% | -44.4% | -0.4% | — |
 NRXP | $85M | -2.3 | — | — | — | -1324.4% | — | — | — |
 JAZZ | $14B | -38.9 | 23.8 | 11.0 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See SKYE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SKYE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SKYE vs ATAI
Side-by-side business, growth, and profitability comparison vs Atai Beckley N.V.
Start ComparisonSKYE — Frequently Asked Questions
Quick answers to the most common questions about buying SKYE stock.
What is Skye Bioscience, Inc.'s P/E ratio?
Skye Bioscience, Inc.'s current P/E ratio is -0.6x. The historical average is 16.5x.
What is Skye Bioscience, Inc.'s ROE?
Skye Bioscience, Inc.'s return on equity (ROE) is -126.8%. The historical average is -54.7%.
Is SKYE stock overvalued?
Based on historical data, Skye Bioscience, Inc. is trading at a P/E of -0.6x. Compare with industry peers and growth rates for a complete picture.